v3.25.2
Condensed Consolidated Statements of Changes in Equity (Statement) - USD ($)
$ in Thousands
Total
Common Units
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Non-controlling Interests
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2023 $ 7,302            
Increase (Decrease) in Temporary Equity [Roll Forward]              
Net loss attributable to redeemable noncontrolling interests (2,285)            
Redeemable noncontrolling interests, ending balance at Mar. 31, 2024 5,017            
Common units balance, beginning of period (in shares) at Dec. 31, 2023 [1]   484,922,828          
Balance, beginning of period at Dec. 31, 2023 1,075,014 $ 496,882     $ 18,561 $ 155,453 $ 404,118
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income attributable to Ardent Health, Inc. 27,047         27,047  
Net income attributable to noncontrolling interests 21,089           21,089
Other comprehensive income (loss) 703       703    
Distributions to noncontrolling interests (14,256)           (14,256)
Vesting of Class C Units (in shares) [1]   464,853          
Issuance of stock 512 $ 512          
Common units balance, ending of period (in shares) at Mar. 31, 2024 [1]   485,387,681          
Balance, ending of period at Mar. 31, 2024 1,110,109 $ 497,394     19,264 182,500 410,951
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2023 7,302            
Redeemable noncontrolling interests, ending balance at Jun. 30, 2024 3,668            
Common units balance, beginning of period (in shares) at Dec. 31, 2023 [1]   484,922,828          
Balance, beginning of period at Dec. 31, 2023 1,075,014 $ 496,882     18,561 155,453 404,118
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income attributable to Ardent Health, Inc. 69,817            
Other comprehensive income (loss) (1,552)            
Common units balance, ending of period (in shares) at Jun. 30, 2024 [1]   485,909,683          
Balance, ending of period at Jun. 30, 2024 1,158,989 $ 497,620     17,009 225,270 419,090
Redeemable noncontrolling interests, beginning balance at Mar. 31, 2024 5,017            
Increase (Decrease) in Temporary Equity [Roll Forward]              
Net loss attributable to redeemable noncontrolling interests (1,349)            
Redeemable noncontrolling interests, ending balance at Jun. 30, 2024 3,668            
Common units balance, beginning of period (in shares) at Mar. 31, 2024 [1]   485,387,681          
Balance, beginning of period at Mar. 31, 2024 1,110,109 $ 497,394     19,264 182,500 410,951
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income attributable to Ardent Health, Inc. 42,770         42,770  
Net income attributable to noncontrolling interests 25,540           25,540
Other comprehensive income (loss) (2,255)       (2,255)    
Distributions to noncontrolling interests (17,401)           (17,401)
Vesting of Class C Units (in shares) [1]   522,002          
Issuance of stock 226 $ 226          
Common units balance, ending of period (in shares) at Jun. 30, 2024 [1]   485,909,683          
Balance, ending of period at Jun. 30, 2024 1,158,989 $ 497,620     17,009 225,270 419,090
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2024 1,158            
Increase (Decrease) in Temporary Equity [Roll Forward]              
Net loss attributable to redeemable noncontrolling interests (1,350)            
Redeemable noncontrolling interests, ending balance at Mar. 31, 2025 (192)            
Common units balance, beginning of period (in shares) at Dec. 31, 2024     142,747,818        
Balance, beginning of period at Dec. 31, 2024 1,521,199 [2]   $ 1,428 $ 754,415 9,737 365,796 389,823
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income attributable to Ardent Health, Inc. 41,383         41,383  
Net income attributable to noncontrolling interests 18,932           18,932
Other comprehensive income (loss) (5,809)       (5,809)    
Vesting of restricted stock unit awards (in shares)     289,946        
Vesting of restricted stock unit awards (1,061)   $ 2 (1,063)      
Distributions to noncontrolling interests (19,239)           (19,239)
Equity-based compensation 9,263     9,263      
Common units balance, ending of period (in shares) at Mar. 31, 2025     143,037,764        
Balance, ending of period at Mar. 31, 2025 1,564,668   $ 1,430 762,615 3,928 407,179 389,516
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2024 1,158            
Redeemable noncontrolling interests, ending balance at Jun. 30, 2025 (1,751)            
Common units balance, beginning of period (in shares) at Dec. 31, 2024     142,747,818        
Balance, beginning of period at Dec. 31, 2024 1,521,199 [2]   $ 1,428 754,415 9,737 365,796 389,823
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income attributable to Ardent Health, Inc. 114,333            
Other comprehensive income (loss) (10,133)            
Common units balance, ending of period (in shares) at Jun. 30, 2025     143,098,506        
Balance, ending of period at Jun. 30, 2025 $ 1,648,126 [2]   $ 1,431 773,422 (396) 480,129 393,540
Balance, ending of period (in shares) at Jun. 30, 2025 143,098,506            
Redeemable noncontrolling interests, beginning balance at Mar. 31, 2025 $ (192)            
Increase (Decrease) in Temporary Equity [Roll Forward]              
Net loss attributable to redeemable noncontrolling interests (1,559)            
Redeemable noncontrolling interests, ending balance at Jun. 30, 2025 (1,751)            
Common units balance, beginning of period (in shares) at Mar. 31, 2025     143,037,764        
Balance, beginning of period at Mar. 31, 2025 1,564,668   $ 1,430 762,615 3,928 407,179 389,516
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income attributable to Ardent Health, Inc. 72,950         72,950  
Net income attributable to noncontrolling interests 24,310           24,310
Other comprehensive income (loss) (4,324)       (4,324)    
Vesting of restricted stock unit awards (in shares)     66,306        
Vesting of restricted stock unit awards (438)   $ 1 (439)      
Distributions to noncontrolling interests (20,286)           (20,286)
Vesting of Class C Units (in shares)     7,553        
Forfeitures of restricted stock awards (in shares)     (13,117)        
Equity-based compensation 11,246     11,246      
Common units balance, ending of period (in shares) at Jun. 30, 2025     143,098,506        
Balance, ending of period at Jun. 30, 2025 $ 1,648,126 [2]   $ 1,431 $ 773,422 $ (396) $ 480,129 $ 393,540
Balance, ending of period (in shares) at Jun. 30, 2025 143,098,506            
[1] See Note 1, Description of the Business and Basis of Presentation - Initial Public Offering and Corporate Conversion, for further discussion.
[2] As of June 30, 2025 and December 31, 2024, the unaudited condensed consolidated balance sheets included total liabilities of consolidated variable interest entities of $315.7
million and $306.4 million, respectively. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion.